NV-MLOGICA
10.8.2021 15:03:17 CEST | Business Wire | Press release
mLogica, a global provider of database, mainframe and application modernization services, today announced it’s releasing the most comprehensive set of tools on the market for mainframe migration to the cloud. It’s a move made possible by their recent acquisition of pioneering Italian mainframe technology firm Reverse Paradigm, as well as several other strategic purchases of key technology players and assets earlier this year.
This follows mLogica’s recent acquisition of the groundbreaking LIBER software suite from French multinational information technology firm Atos. The LIBER tool set lets firms with outdated mainframe applications gain the flexibility, scalability and adaptability only possible in the cloud—while retaining all the stability and functionality of their existing systems.
Longtime experts in database and application modernization to the cloud, with these acquisitions mLogica now offers the most complete migration tool set for both private and public sector organizations that can no longer delay updating their antiquated IT systems. The combined toolset will now be marketed as the LIBER*M Mainframe Modernization Suite .
Says mLogica president and CEO Amit Okhandiar, “One of the most important considerations when approaching a complex project like legacy system modernization is the impact it could have on your business’s day-to-day operations. The more moving parts, the more time-consuming, error-prone and logistically challenging it becomes.”
Okhandiar feels simplifying the modernization process is key for customer success. “With these purchases of Reverse Paradigm and the LIBER suite, mLogica is now the one firm that can provide end-to-end expertise, tools and support for every phase of modernization to the cloud. We streamline the entire process so our clients, and their IT staff, can focus on their daily business—knowing they can trust us to deliver on-time, on-budget and with complete accuracy and security.”
mLogica Senior VP of Solution Architecture and Global Operations, Anthony Veltri concurs, “The most exciting aspect of this purchase is that the tools we’ve acquired can be leveraged when we collaborate on projects with our long-standing partners in mainframe migration and system integration, as well as with global cloud providers.”
“These new acquisitions significantly advance our mission to provide our clients with the most comprehensive set of tools on the market, plus expert service and support, which allows them to dramatically reduce the timeline, risks and cost of modernizing workloads of all sizes.”
Reverse Paradigm’s founder and president, Santino Spagnoli, who will now become mLogica’s VP of Engineering for Mainframe Modernization, feels the move points the way to the future of information technology. “We’re excited to become part of a solution-focused organization, which allows us to provide even greater support to our migration partners—and accelerate innovation for the mainframe modernization market.”
About mLogica
mLogica’s mission is to help drive enterprise efficiency through cloud migration. Founded by professionals from leading technology companies, mLogica specializes in migrating complex, legacy on-premise business applications and databases, both mainframe and distributed, to the cloud.
mLogica leverages its automated distributed systems modernization software suite STAR*M , and their mainframe modernization software, LIBER*M , to migrate legacy systems to the cloud. mLogica also modernizes big data applications with their hyperscale petabyte+ big data software CAP*M , and their software-driven TRAK*M managed services programs.
For more information, visit https://www.mLogica.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005338/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom